Novel Factor XI Inhibitor Fast Tracked for Thrombosis Associated With Cancer
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Thromboembolic Disorders
Novel Antithrombotic Fast Tracked for Noncardioembolic Ischemic Stroke
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
Xarelto Approved to Treat and Prevent Blood Clots in Pediatric Patients
A new oral suspension formulation of Xarelto has also been approved by the FDA.
Thromboembolic Disorder Assessment: DVT/PE
Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Thromboembolic Disorders: Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Pradaxa Approved to Treat, Prevent VTE in Pediatric Patients
Pradaxa oral pellets are supplied in child-resistant packets in 20mg, 30mg, 40mg, 50mg, 110mg, and 150mg dosage strengths.
Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease
The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.
Rivaroxaban Prevents VTE After Lower-Limb Surgery
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...